MSD
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From MSD
Taisho Makes Japan Vornorexant Filing, Hopes To Dent Insomnia Market
Taisho’s in-house insomnia therapeutic candidate vornorexant offers a potential advantage of a shorter half-life compared to its competitors, which can contribute to patients’ QOL.
Former Hilleman CEO On Microbiome Project, Cholera, Halal Vaccine
Human milk could have a role in preventing Alzheimer’s disease and other ailments linked to the gut microbiome, says former Pfizer VP and Hilleman CEO Davinder Gill. He also talks about a halal meningitis vaccine, and tailwinds for an oral cholera vaccine now launched by Bharat Biotech in this fascinating interview
India Inc Calls For Regulatory Easing; Looks To Biosimilar Launches Including Keytruda
Speaking of an impending launch of new biosimilars, including pembrolizumab, panelists at a recent event in India asked for regulatory easing from a waiver of Phase III trials for biosimilars to a single body for pre-clinical and trial approvals. The chicken and egg question of VC funding also came up.
New Zealand Gets Cracking On NZD$604m Drug Funding Boost; Starts Repealing Landmark Law
Two targeted treatments for six different types of cancer and two antifungal drugs are the first products that Pharmac has proposed should be funded after it received a boost to its budget in June. Separately, the government is seeking feedback on a bill to repeal the sweeping new therapeutic products law that was passed by its predecessor.
Company Information
- Industry
- Pharmaceuticals
- Other Names / Subsidiaries
-
- Merck Sharpe & Dome
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice